Recruiting

MR-Linac

Sponsor:

UMC Utrecht

Code:

NCT04075305

Conditions

Oncology

Breast Cancer

Prostate Cancer

Gynecologic Cancer

Brain Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radiation therapy

Study Details

Brief summary:

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

Conditions

Oncology

Breast Cancer

Prostate Cancer

Gynecologic Cancer

Brain Tumor

Study ID

NCT04075305

Start date

Feb 1, 2019

Status verified date

Jan, 2026

Completion date

Aug 1, 2030

Anticipated

Primary completion date

Feb 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;
  • Patient provides written, informed consent;
  • Patient is 18 years old or older.

Exclusion Criteria:

  • MRI exclusion criteria, including
  • MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.

Study Design

Enrollment

8000 participants

Anticipated

Interventions and Outcome Measures

Arms

Brain cancer

Lung cancer

Esophageal cancer

Breast Cancer

Head and Neck Cancer

Pancreatic cancer

Gynecological cancer

Rectal cancer

Prostate cancer

Bladder cancer

Oligometastases

Liver cancer

Other types of cancer

Interventions

Radiation therapy

Radiation therapy on the CE marked and FDA approved MR-Linac

Primary outcome measure

  • Progression-free Survival [ Time Frame: 3 months after MR-Linac treatment ]
  • Progression-free Survival [ Time Frame: 6 months after MR-Linac treatment ]
  • Progression-free Survival [ Time Frame: 24 months after MR-Linac treatment ]
  • Survival [ Time Frame: 3 months after MR-Linac treatment ]
  • Survival [ Time Frame: 6 months after MR-Linac treatment ]
  • Survival [ Time Frame: 24 months after MR-Linac treatment ]
  • Disease-free Survival [ Time Frame: 3 months after MR-Linac treatment ]
  • Disease-free Survival [ Time Frame: 6 months after MR-Linac treatment ]
  • Disease-free Survival [ Time Frame: 24 months after MR-Linac treatment ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 3 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 6 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 12 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 24 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 3 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 6 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 12 months after treatment. ]
  • Patient reported Health related quality of life (HRQoL). [ Time Frame: 24 months after treatment. ]
  • Patient reported tumor specific quality of life (QoL). [ Time Frame: 3 months after treatment. ]
  • Patient reported tumor specific quality of life (QoL). [ Time Frame: 6 months after treatment. ]
  • Patient reported tumor specific quality of life (QoL). [ Time Frame: 12 months after treatment. ]
  • Patient reported tumor specific quality of life (QoL). [ Time Frame: 24 months after treatment. ]
  • Acute toxicity in common toxicity criteria for adverse events (CTCAE). [ Time Frame: 3 months after treatment. ]
  • Acute toxicity in common toxicity criteria for adverse events (CTCAE). [ Time Frame: 6 months after treatment. ]
  • Acute toxicity in common toxicity criteria for adverse events (CTCAE). [ Time Frame: 12 months after treatment. ]
  • Acute toxicity in common toxicity criteria for adverse events (CTCAE). [ Time Frame: 24 months after treatment. ]
  • Clinical tumor response. [ Time Frame: 2 year follow up. ]
  • Pathological tumor response. [ Time Frame: 2 year follow up. ]
  • Toxicity in common toxicity criteria for adverse events (CTCAE). [ Time Frame: 2 years ]

Central Contacts and Locations

Central contacts

Tessa Leer

T +31 (0)88 75 63707T.Leer@umcutrecht.nl

Locations

Allegheny Health Network

Recruiting

Pittsburgh, Pennsylvania, United States, 15212

Md Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Clifton D Fuller

(713) 745-4404cdfuller@mdanderson.org

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Sunnybrook Health Sciences Centre/Odette Cancer Centre

Recruiting

Toronto, Ontario, Canada

University Health Network - Princess Margaret Cancer Center

Recruiting

Toronto, Canada

More Information

Sponsor

UMC Utrecht

Last update posted

Mar 5, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by UMC Utrecht on 2026-03-05.